Bernard Chiasson

Bernard is the Vice President Operations & Chief Scientific Officer. Dr. Chiasson has 25 years of experience in pharmaceuticals and biotechnology. He has held positions of increasing responsibility in Research and Development and executive management.

During his time in industry, he has worked on several small molecules, biologics and biotechnology products at various stages of product development, including the final registration phase in Canada, the U.S. and Europe. He has held positions of increasing responsibility during his career with Novartis, Draxis Health, Bayer Biologics, Amgen, Optum and Tribute Pharmaceuticals Inc. (Tribute). Most recently, he was Chief Scientific Officer at Tribute and part of the executive team that grew the company to a final merger that saw a rise of approximately ten times in market capitalization during his tenure. Prior to Tribute, he was Vice President of US Strategic Regulatory Affairs and Global Medical Services at Optum where he was responsible for a team of scientists and physicians supporting client drug development, safety and regulatory strategies and operations.

Dr. Chiasson is a trained neuroscientist and pharmacologist and received a BSc (hons), MSc. (Physiology and Biophysics) and PhD (Neuroscience and Pharmacology) from Dalhousie University and conducted his Post-Doctoral studies at the University of Toronto.